25Jul/13

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter … – DailyFinance

Monoclonal Anti-CD20 Antibodies

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter …
DailyFinance
We estimate that approximately $82 million of TECFIDERA revenues in the second quarter represent inventory in the channel while revenue generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from …
Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking Alpha

all 30 news articles »
25Jul/13

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter … – MarketWatch

Monoclonal Anti-CD20 Antibodies

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter …
MarketWatch
RITUXAN(R) (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. “With a strong start for TECFIDERA in the U.S., as well as approvals in …
Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking Alpha

all 27 news articles »
25Jul/13

Gilead Sciences Announces Second Quarter 2013 Financial Results – DailyFinance

Monoclonal Anti-CD20 Antibodies

Gilead Sciences Announces Second Quarter 2013 Financial Results
DailyFinance
Results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101) in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia. This regimen achieved a complete response rate of 19 percent and an …
Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call …Seeking Alpha

all 24 news articles »
25Jul/13

Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance – StreetInsider.com (subscription)

Monoclonal Anti-CD20 Antibodies

Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance
StreetInsider.com (subscription)
… generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012.

and more »
24Jul/13

Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer … – DailyFinance

Monoclonal Anti-CD20 Antibodies

Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer …
DailyFinance
… monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab …
Roche antibody tops Rituxan in blood cancer CLLPMLiVE
Genentech Trumpets Phase III Results for CLL CandidateGenetic Engineering News

all 11 news articles »
24Jul/13

Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Merck … – HispanicBusiness.com

Monoclonal Anti-CD20 Antibodies

Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Merck …
HispanicBusiness.com
… monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab …

and more »